Key result
Simvastatin and ezetimibe did not significantly reduce the primary composite of major cardiovascular events compared with placebo (HR 0.96; 95% CI 0.83-1.12; p=0.59) but reduced ischemic cardiovascular events.
Why the study?
Does statin therapy reduce the progression of aortic stenosis and improve cardiovascular outcomes in patients with aortic stenosis?
Does statin therapy reduce the progression of aortic stenosis and improve cardiovascular outcomes in patients with aortic stenosis?
Hazard Ratio: 0.96 (95% CI 0.83–1.12)
Absolute Event Rate: 35.3% vs 38.2%
p-value: p=0.59
Authors
No takes yet. Share an insight, caveat, or question.
Statins may offer cardiovascular benefits in patients with aortic stenosis by reducing ischemic events, even if they do not slow the hemodynamic progression of the valve disease.
Kosmas I. Paraskevas (2009) conducted a letter in Aortic stenosis. Simvastatin and ezetimibe vs. Placebo was evaluated on Composite of major cardiovascular events, including death from cardiovascular causes, aortic valve replacement, non-fatal myocardial infarction, hospitalisation for unstable angina pectoris, heart failure, coronary artery bypass grafting, percutaneous coronary intervention and non-haemorrhagic stroke (HR 0.96, 95% CI 0.83-1.12, p=0.59). Simvastatin and ezetimibe did not significantly reduce the primary composite of major cardiovascular events compared with placebo (HR 0.96; 95% CI 0.83-1.12; p=0.59) but reduced ischemic cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: